Dr. Jaishree Manohar, M.D.
What this data tells you about Dr. Manohar
Dr. Jaishree Manohar is a rheumatology in Sarasota, FL, with 15 years in practice. Based on federal Medicare data, Dr. Manohar performed 157,103 Medicare services across 1,674 unique beneficiaries.
Between the years covered by Open Payments, Dr. Manohar received a total of $25,558 from 41 pharmaceutical and/or device companies across 980 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Manohar is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
Medicare Practice Summary
Medicare Utilization ↗Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Certolizumab injection (Cimzia) | 59,400 | $4 | $20 |
| Tocilizumab injection (Actemra) | 35,230 | $5 | $10 |
| Golimumab infusion (Simponi Aria) | 29,750 | $10 | $50 |
| Abatacept infusion (Orencia) | 12,488 | $34 | $100 |
| Denosumab injection (Prolia/Xgeva) | 7,620 | $18 | $27 |
| Romosozumab injection (Evenity) for osteoporosis | 6,510 | $8 | $12 |
| Injection, rituximab, 10 mg | 1,702 | $63 | $175 |
| Infliximab infusion (Remicade) | 1,410 | $26 | $110 |
| Office visit, established patient (30-39 min) | 1,080 | $93 | $289 |
| Drug injection, under skin or into muscle | 494 | $11 | $30 |
| Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | 351 | $50 | $100 |
| Methotrexate sodium, 5 mg | 271 | $0 | $5 |
| Administration of chemotherapy into vein, 1 hour or less | 171 | $101 | $550 |
| Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | 99 | $56 | $150 |
| Injection, zoledronic acid, 1 mg | 80 | $7 | $50 |
| Joint injection, major joint | 71 | $50 | $160 |
| Administration of chemotherapy into vein, each additional hour | 70 | $22 | $150 |
| Dxa bone density measurement of hip, pelvis, spine including spine fracture assessment | 62 | $50 | $125 |
| Office visit, established patient (20-29 min) | 61 | $62 | $200 |
| Injection, methylprednisolone acetate, 40 mg | 42 | $6 | $14 |
| Injection of additional new drug or substance into vein | 34 | $12 | $34 |
| Office visit, established patient, complex (40-54 min) | 34 | $132 | $273 |
| Hyaluronan or derivative, gel-one, for intra-articular injection, per dose | 30 | $406 | $1,500 |
| Injection, methylprednisolone sodium succinate, up to 125 mg | 26 | $4 | $20 |
| Injection, methylprednisolone acetate, 80 mg | 17 | $9 | $38 |
Industry Payment Transparency
Open Payments through 2024 ↗Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
Payments by company (2024)
Associated products mentioned in payments ›
Most payments (88%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →
Summary
Dr. Manohar is a mixed practice specialist, with above-average Medicare volume (top 15% in FL), and high industry engagement (low-engagement, top 17%), with 15 years of practice experience.
This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →
Frequently Asked Questions
Is Dr. Manohar experienced with certolizumab injection (cimzia)?
Does Dr. Manohar receive payments from pharmaceutical companies?
How do Dr. Manohar's costs compare to other rheumatologys in Sarasota?
What does Data Coverage mean?
Is this data up to date?
Explore related providers
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology